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Purpose/Objective: The increase in life expectancy leads to 
an increased number of elderly patients (pts) diagnosed with 
NSCLC. Octogenarians can be a treatment challenge due to 
frailty and comorbidity. Stereotactic Body Radiotherapy 
(SBRT) has become the standard treatment for medical 
inoperable pts with early stage NSCLC. However, it is 
unknown if all pts have same benefit of SBRT due to lack of 
randomized studies. This retrospective single-institution 
study reports survival and control rates for medical 
inoperable octogenarians vs. pts <80 years old with early 
stage NSCLC treated with SBRT. 
Materials and Methods: All records of pts treated with SBRT 
in our institution from 2005 to 2014 were reviewed. The 
thoracic RT consisted of 45-66 Gy/3F delivered in 9 days. The 
majority of the tumors were histological or cytological proven 
NSCLC T1-2N0M0. Pts were divided into two cohorts, age ≥80 
and <80. Kaplan-Meier and Cox proportional hazard analyses 
were used for uni- and multivariable survival analyses, 
respectively. Overall survival (OS), local failure-specific 
survival (LFS), and distant recurrence-free survival (DRFS) 
were compared. 
Results: A total of 187 pts were identified. Of these, 50 were 
≥80 and 137 were <80. Median follow-up was 31.2 months. 
Statistically significant (p<0.05) inter-group differences in 
patient characteristics were observed: Fraction of female 
population 26% vs 62%, fraction smoking within the last 10 
years 38% vs 17%, fraction of pts with stage T1 58% vs 77%, 
for the groups ≥80 and <80, respectively. No differences in 
PS, radiation dose, clinical vs. pathological diagnosis of 
NSCLC, histology, mediastinal staging, or PET scans at time of 
diagnosis between the two groups were observed (all 
p>0.05). No difference in comorbidity measured by Charlson 
Score Index was observed. SBRT was generally well tolerated.  
A log rank test showed a significant difference of OS between 
patients ≥80 and <80 (p=0.02) e.g. resulting in an OS at 5-
year of 31% vs. 36% respectively. A trend in difference of LFS 
was observed (p=0.07) favoring pts <80 e.g. 5 year LFS of 58% 
vs. 72%, ≥80 and <80 respectively, There was no difference in 
DRFS between ≥80 and <80 (p=0.17), e.g. 5-year DRFS 50% vs. 
80%. To compensate for differences in the patient 
characteristics, Cox regression multivariable analyses on 
survival rates were performed. The analysis for OS indicated 
that PS 2+ and age80+ were significant factors and associated 
with poorer prognosis. Age 80+ was also significant factor and 
associated with poorer prognosis in the analysis of LFS (table 
1). 
 
Conclusions: Within the limitations of this study, 
octogenarians undergoing SBRT achieved similar DFRS 
compared to younger pts. The octogenarians had significantly 
shorter OS and significantly shorter LFS than pts <80. 
However, SBRT is still a potential curative treatment for 
octogenarians with early-stage NSCLC not fit for surgery.  
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Purpose/Objective: To evaluate the effectiveness of a body 
emulsion containing 0.25% hyaluronic acid, 0.25% chondroitin 
sulfate, Aloe vera, carrot oil, vitamin F and vitamin E for 
preventing and treating skin toxicity in breast cancer patients 
(BCP) undergoing radiotherapy (RT). 
Materials and Methods: A randomized, open-label, 
controlled single-center study was made involving 60 BCP 
undergoing RT, and a historical series of 30 controls. The 60 
patients were divided into two groups of 30 subjects each 
(prevention group: emulsion use starting 2 weeks before 
radiotherapy; and treatment group: emulsion use starting 
upon appearance of skin problems). The two groups were 
compared with a historical series of 30 controls who received 
no specific dermatological treatment. 
Results: A total of 90 patients were included, with a mean 
age of 60.75 years (SD 9.6). Significant differences (p<0.0001) 
were observed among the 3 groups in terms of the 
development of dermal toxicity based on the RTOG/EORTC 
criteria. The controls accumulated a larger number of dermal 
toxicity manifestations (184 vs 103 in the treatment group 
and 80 in the prevention group). Time to appearance of skin 
toxicity after starting radiotherapy was significantly longer in 
the prevention group than in the control series (51.72 vs. 
42.23 days, respectively; p=0.01). 4 patients presented mild 
allergic skin reactions resolved with suppression of the 
emulsion. The product characteristics were very positively 
rated by the patients. The percentage of positive responses 
(quite satisfied/very satisfied) in reference to general 
satisfaction, rapid absorption, more hydrated and soft skin, 
easy application, symptoms improvement and rapidity of 
symptom relief being 97.05%, 97.04%, 96.75%, 96.73%, 96.45% 
and 94.97%, respectively.  
Conclusions: The body emulsion with hyaluronic acid and 
chondroitin sulfate is effective both in delaying the 
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appearance of skin toxicity and in reducing the number of 
dermal toxicity manifestations in BCP subjected to RT. 
Patient satisfaction was highly positive in the majority of 
cases 
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Purpose/Objective: The purpose of the current clinical trial 
was to evaluate efficiency of palliative external beam 
radiotherapy for symptomatic bone metastases from different 
primary tumors and to search for optimum treatment 
schedules. 
Materials and Methods: The randomized study included 427 
patients treated for 616 sites of bone lesions. Breast was the 
primary site in 67% of cases, prostate - in 7%, lung - in 8%, 
renal - in 6%, other tumors, including sarcomas, melanoma, 
colon cancer and unknown primary site - in 12%. The most 
frequent treatment site was the spine - 48%, followed by 
pelvis - 34%, long bones - 14% and other sites - 4%. The main 
indication for irradiation was pain not alleviated by 
sistematic drug therapy (chemotherapy, target therapy, 
bisphosphonates). Radiotherapy protocol included 
hypofractionation regimes of 2, 3 or 4 fractions of 6,5 Gy 
daily, every two days or every five days and standard 
treatment schedule of 23 fractions of 2 Gy daily. 
Results: The average follow-up period was 41 months. 
General pain relief (complete and partial) was observed in 
95,8% - 100% of sites and was independent of primary tumor, 
metastases localization and irradiation schedules. Complete 
response rate (CRR) was higher for bone metastases from 
breast and prostate cancer 67% and 64% correspondingly in 
comparison with lung and renal cancer - 55% and 33% 
respectively (p<0,05). At small number of observations 
metastases from melanoma and sarcomas proved high 
radiosensitivity with CRR 75% and 69% correspondingly. CRR 
for spine and pelvis localization of metastases was similar - 
63,4% and 59,3%, slightly lower for long bones - 48,3% and 
significantly lower for sacrum isolated metastases - 27% 
(p<0,05). CRR significantly increased from 43,6% to 47,9% and 
64,4% for 2, 3 and 4 fractions of 6,5 Gy correspondingly 
(p<0,03). The pain relapse rate in irradiated zone was 8,2% 
and detected no correlation with histology type, metastatic 
site, dose and fractionation schedules. The acute toxicity 
rate (RTOG/EORTC) comprised 24-32% independently of 
irradiation regimes. Late radiation morbidity was observed in 
15,7% for standard treatment schedule and decreased in 
consecutive way for 4, 3 and 2 fractions of 6,5 Gy (14,4%, 
10,9% and 8,3% respectively). Late toxicity grade 2 was 
significantly lower (1,7%, p<0,05) for 3 fractions regime. 
Conclusions: Histogenesis of primary tumor is a predictor of 
radiosensitivity of bone metastases, it significantly affects 
the complete pain response rate. It is expedient to use 
hypofractionation regimes of 3 fractions of 6,5 Gy (total dose 
19,5 Gy) for palliative radiotherapy for bone metastases in 
case of breast and prostate cancer and 4 fractions of 6,5 Gy 
(total dose 26 Gy) in case of lung and renal cancer daily, 
every two days or every five days. In the multifactorial 
analysis tumor primary site and pain intensity before 
radiotherapy were the only independent prognostic factors of 
CRR.  
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Purpose/Objective: The assessment of response to 
radioembolization (RE) of liver metastases is difficult because 
the effect of the radiation on tumour burden is quite 
different from those of chemotherapeutic agents, and 
patients undergo this treatment after multiple systemic and 
regional therapies which determine dramatic changes in liver 
density - caused by necrosis or sclerosis. 18F-FDG-PET/CT has 
been documented as a powerful tool in this respect, 
nonetheless there is not agreement about the optimal 
imaging choice (CT vs. FDG-PET/CT). We investigated the 
accuracy of different parameters derived from CT and 18F-
FDG PET/CT in early predicting the outcome after RE 
Materials and Methods: Patients with chemo-refractory liver 
metastases from solid tumours scheduled to receive RE 
underwent 18F-FDG-PET/CT and CT scan before and 6 weeks 
after RE. Response to treatment was assessed in PET 
according to PERCIST criteria, and metabolic tumour volume 
(MTV), in CT according to RECIST criteria. Overall survival 
(OS) rates were calculated using the Kaplan Meyer method, 
and differences among scoring criteria were explored with 
the log-rank test 
Results: 22 patients were suitable for analysis. All patients 
received a single treatment of RE, with a median activity of 
1.7 GBq (range 0.6-2.9) of 90Y microspheres. Metabolic 
response correlated significantly with OS. For PERCIST, the 
median OS was 28.4 months (95 % CI, 12.4–44.4 mo) in 
patients with CR, 17.7 mo (5.0–30.5 mo) in patients with PR 
and 4.8 mo (2.9–6.8 mo) in those who had SD (see Figure 1). 
All these differences were statistically significant (p<0.05). 
Moreover, responders (CR+PR) had a median OS of 20.6 mo 
(5.7–35.5 mo) with a significant longer OS compared to those 
who showed SD. 
MTV did not produce the expected results, i.e. did not 
correlate with the survival. In several patients we 
experienced some difficulty in defining lesion margins and 
establishing a threshold vs the surrounding liver parenchyma. 
Concerning RECIST criteria, there was no straight separation 
between patients who responded to RE and those who did 
not. The median OS for patients with PR, SD and PD was 20.6 
(14.5-32.8 months), 11.8 (7.9-29.6 months), and 2.7 months 
(0-15.5 months), respectively. Despite the median response 
values were separated, the statistical analysis of the survival 
curves did not reveal any significant difference among the 
four scores (CR, PR, SD, PD).  
